Presentation is loading. Please wait.

Presentation is loading. Please wait.

Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection  Shamir R. Jacobino, MS, Maaike Nederend, BS, Marije.

Similar presentations


Presentation on theme: "Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection  Shamir R. Jacobino, MS, Maaike Nederend, BS, Marije."— Presentation transcript:

1 Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection 
Shamir R. Jacobino, MS, Maaike Nederend, BS, Marije Hennus, MD, PhD, Michiel L. Houben, MD, PhD, Joan O. Ngwuta, BS, Marco Viveen, BS, Frank E.J. Coenjaerts, PhD, C. Erik Hack, MD, PhD, R.J. Joost van Neerven, PhD, Barney S. Graham, MD, PhD, Louis Bont, MD, PhD, Jeanette H.W. Leusen, PhD  Journal of Allergy and Clinical Immunology  Volume 138, Issue 5, Pages e5 (November 2016) DOI: /j.jaci Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Human AF contains RSV-neutralizing antibodies. Total IgG (A) and RSV-specific IgG (B) concentrations in AF. RSV-neutralizing activity of (C) palivizumab and (D) AF. E, Fusion protein competition neutralization assay. F, AF RSV-GFP neutralization. EVND, Equivalent virus neutralization dose; GFP, Green fluorescent protein. AF 6 and AF 7 refer to different AF donors. Results in Fig 1, C and F, represent mean ± SD of triplicate measurements. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Intranasal administration of AF protects against RSV infection. RSV titers in bronchoalveolar lavage fluid (BALF). Palivizumab prophylaxis 1 day (A), 1 to 7 days (0.5 mg/kg) (B), and 3 days (0.5 mg/kg) (C) before infection. D, Palivizumab and AF prophylaxis 1 day before infection. Wild-type mice were used, except for Fcer1g−/− mice in Fig 2, C. N = 4 to 5 mice/group (median ± interquartile range; Mann-Whitney test, *P < .05; **P < .01). Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig E1 Human AF contains RSV-specific IgA antibodies. Total IgA (A) and RSV-specific IgA (B) concentrations in AF. C-F, Fusion protein competition neutralization assay. The prefusion RSV F protein concentration used in this assay was not sufficient to fully inhibit the RSV-neutralizing activity of AF 3 and AF 10. AF 3, AF 10, AF 11, and AF 15 refer to different AF donors. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E2 AF antibodies bind specifically to RSV-infected HEp-2 cells. AF IgG binding to (A) uninfected HEp-2 cells and (B) RSV-infected HEp-2 cells. MFI, Mean fluorescence intensity. The red line indicates background binding of AF IgG to uninfected cells. Results represent mean ± SD of triplicate measurements. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E3 AF IgG neutralizes RSV. A and C, Total IgG concentrations. B, RSV-neutralizing activity. D, RSV lung titers of WT mice treated with palivizumab or AF 1 day before infection. GFP, Green fluorescent protein. N = 5 mice/group (median ± interquartile range; Mann-Whitney test, **P < .01). AF 2, AF 4, and AF 6 refer to different AF donors. Results in Fig E3, A-C, represent mean ± SD of triplicate measurements. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E4 RSV-neutralizing activity of human CB. Total IgG (A) and RSV-specific IgG (B) concentrations in CB. C, RSV-neutralizing activity of CB. EVND, Equivalent virus neutralization dose. N = 20 donors. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions


Download ppt "Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection  Shamir R. Jacobino, MS, Maaike Nederend, BS, Marije."

Similar presentations


Ads by Google